ISSN 1662-4009 (online)

ey0016.9-12 | Cancer Treatment and Growth Disorders | ESPEYB16

9.12. Diagnosis of GH deficiency as a late effect of radiotherapy in survivors of childhood cancers

JG Sfeir , NEN Kittah , SU Tamhane , S Jasim , W Chemaitilly , LE Cohen , MH Murad

To read the full abstract: J Clin Endocrinol Metab. 2018 Aug 1; 103(8):2785GH deficiency (GHD) is common among children treated for cancer, especially among childhood cancer survivors (CCS) with tumors/surgery in the hypothalamic-pituitary (HP) region, CCS exposed to HP radiation or CCS exposed to cranial (CIR), craniospinal (CSI), or total body irradiation (TBI). However, most of existi...

ey0016.9-14 | Cancer Treatment and Growth Disorders | ESPEYB16

9.14. GH therapy in childhood cancer survivors: a systematic review and meta-analysis

S Tamhane , JG Sfeir , NEN Kittah , S Jasim , W Chemaitilly , LE Cohen , MH Murad

To read the full abstract: J Clin Endocrinol Metab. 2018 Aug 1; 103(8): 2794This systematic review and meta-analysis was conducted by a US Endocrine Society Task Force in order to inform new guidelines on the management of childhood cancer survivors (CCS). The aim of this review was to evaluate the effects of GH therapy on final height, risk of diabetes mellitus, lipid abnormalities, met...

ey0020.7-13 | Long-Term Surveillance for Endocrine Complications in Childhood Cancer Survivors | ESPEYB20

7.13. Management of childhood cancer survivors at risk for thyroid function abnormalities: A Delphi study

JJG Welch , B Ames , LE Cohen , E Gaufberg , MM Hudson , PC Nathan , L Nekhlyudov , TI Yock , W Chemaitilly , LB Kenney

Brief summary: This study used a Delphi approach to generate consensus guidelines for screening of asymptomatic childhood cancer survivors for thyroid dysfunction and recommendations for the management of abnormal thyroid screening results.A Delphi panel of 40 clinical experts (oncologists, endocrinologists, and primary care physicians) participated in three rounds of anonymous questionnaires, formatted as clinical scenarios. Consensus was defined by agr...

ey0017.4-1 | Important for clinical practice | ESPEYB17

4.1. Diagnosis, genetics, and therapy of short stature in children: A growth hormone research society international perspective

PF Collett-Solberg , G Ambler , PF Backeljauw , M Bidlingmaier , BMK Biller , MCS Boguszewski , PT Cheung , CSY Choong , LE Cohen , P Cohen , A Dauber , CL Deal , C Gong , Y Hasegawa , AR Hoffman , PL Hofman , R Horikawa , AAL Jorge , A Juul , P Kamenicky , V Khadilkar , JJ Kopchick , B Kristrom , MdLA Lopes , X Luo , BS Miller , M Misra , I Netchine , S Radovick , MB Ranke , AD Rogol , RG Rosenfeld , P Saenger , JM Wit , J Woelfle

To read the full abstract: Horm Res Paediatr. 2019;92:1–14In March 2019, 46 international experts from 14 countries across 5 continents attended a 3-day workshop organized by the Growth Hormone Research Society (GRS) and produced this perspective on the diagnosis, management and therapy in children with short stature. In this context, this expert panel tackled almost all aspects related to the management of children with short stature, prov...

ey0019.9-1 | Cancer treatment and growth hormone therapy: a consensus | ESPEYB19

9.1. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement

MCS Boguszewski , CL Boguszewski , W Chemaitilly , LE Cohen , J Gebauer , C Higham , AR Hoffman , M Polak , KCJ Yuen , N Alos , Z Antal , M Bidlingmaier , BMK Biller , G Brabant , CSY Choong , S Cianfarani , PE Clayton , R Coutant , AA Cardoso-Demartini , A Fernandez , A Grimberg , K Guðmundsson , J Guevara-Aguirre , KKY Ho , R Horikawa , AM Isidori , JOL Jorgensen , P Kamenicky , N Karavitaki , JJ Kopchick , M Lodish , X Luo , AI McCormack , L Meacham , S Melmed , Moab S Mostoufi , HL Muller , SJCMM Neggers , Oliveira MH Aguiar , K Ozono , PA Pennisi , V Popovic , S Radovick , L Savendahl , P Touraine , HM van Santen , G Johannsson

n.karavitaki@bham.ac.uk Eur J Endocrinol. 2022; 186: P35-P52. PMID: 35319491.Brief Summary: An international panel of experts produced this consensus statement after critical review of the existing evidence on the safety of GH replacement in cancer and intracranial tumour survivors and in patients with increased cancer risk. Current evidence does not support an association betwe...

ey0020.7-14 | Long-Term Surveillance for Endocrine Complications in Childhood Cancer Survivors | ESPEYB20

7.14. Hypothalamic-pituitary and other endocrine surveillance among childhood cancer survivors

L van Iersel , RL Mulder , C Denzer , LE Cohen , HA Spoudeas , LR Meacham , E Sugden , AYN Schouten-van Meeteren , EW Hoving , RJ Packer , GT Armstrong , S Mostoufi-Moab , AM Stades , D van Vuurden , GO Janssens , C Thomas-Teinturier , RD Murray , N Di Iorgi , SJCMM Neggers , J Thompson , AA Toogood , H Gleeson , C Follin , E Bardi , L Torno , B Patterson , V Morsellino , G Sommer , SC Clement , D Srivastava , CE Kiserud , A Fernandez , K Scheinemann , S Raman , KCJ Yuen , WH Wallace , LS Constine , R Skinner , MM Hudson , LCM Kremer , W Chemaitilly , HM van Santen

Brief summary: In this extensive and updated review, the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) report expert consensus-based guidelines that harmonize recommendations for surveillance of endocrine disorders in childhood cancer survivors.This interdisciplinary panel of 42 international experts formulated new surveillance recommendations for hypothalamic–pituitary (HP) dysfunction. Existing IGHG surveillan...